Ying Hu1, Ning Zhou, Ru Wang. 1. Department of Pharmacy, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Abstract
PURPOSE: The purpose of this study was to elucidate the influence of Apatinib combined with cisplatin on changing the phenotypes of TPC-1 cells. METHODS: VEGFR2 levels in thyroid carcinoma tissues and adjacent normal ones were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Then, the viability of TPC-1 cells induced with different doses of Apatinib and cisplatin was determined by cell counting kit-8 (CCK-8). Migratory and invasive abilities and apoptosis of TPC-1 cells induced with Apatinib combined with cisplatin were assessed. The protein levels of p-VEGFR2, VEGFR2, p-Akt, Akt, p-mTOR and mTOR in TPC-1 cells influenced by the treatment of Apatinib combined with cisplatin were examined by Western blot. RESULTS: VEGFR2 was upregulated in thyroid carcinoma tissues. Cisplatin treatment markedly suppressed viability, migratory and invasive abilities, and stimulated apoptosis of TPC-1 cells, which were further strengthened by combination treatment of Apatinib. Apatinib treatment strengthened the anti-tumor influence of cisplatin on TPC-1 cells through downregulating p-VEGFR2, p-Akt and p-mTOR. CONCLUSIONS: Apatinib strengthens the anti-tumor influence of cisplatin in thyroid carcinoma through VEGFR2-Akt-mTOR pathway.
PURPOSE: The purpose of this study was to elucidate the influence of Apatinib combined with cisplatin on changing the phenotypes of TPC-1 cells. METHODS: VEGFR2 levels in thyroid carcinoma tissues and adjacent normal ones were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Then, the viability of TPC-1 cells induced with different doses of Apatinib and cisplatin was determined by cell counting kit-8 (CCK-8). Migratory and invasive abilities and apoptosis of TPC-1 cells induced with Apatinib combined with cisplatin were assessed. The protein levels of p-VEGFR2, VEGFR2, p-Akt, Akt, p-mTOR and mTOR in TPC-1 cells influenced by the treatment of Apatinib combined with cisplatin were examined by Western blot. RESULTS: VEGFR2 was upregulated in thyroid carcinoma tissues. Cisplatin treatment markedly suppressed viability, migratory and invasive abilities, and stimulated apoptosis of TPC-1 cells, which were further strengthened by combination treatment of Apatinib. Apatinib treatment strengthened the anti-tumor influence of cisplatin on TPC-1 cells through downregulating p-VEGFR2, p-Akt and p-mTOR. CONCLUSIONS: Apatinib strengthens the anti-tumor influence of cisplatin in thyroid carcinoma through VEGFR2-Akt-mTOR pathway.